VerImmune Awarded ~$470K CDMRP Grant to Drive Innovation in ViP-Based Therapeutics for Advanced Melanoma

Washington DC & Singapore – April 29th, 2025- VerImmune, Inc. (“VerImmune”), a biotechnology company developing innovative Virus-inspired Particle (ViP) modalities, announced today it has been awarded a ~$470,000 USD research grant (MRP Idea Award) from the U.S. Department of Defense (DoD) Melanoma Research Program (MRP), managed by the office of Congressionally Directed Medical Research Programs (CDMRP).

The award will support the development of novel candidates based on VerImmune’s ViP technology for the treatment of advanced or rare melanoma cancers.

The MRP received 136 compliant applications and recommended funding for only nine, placing VerImmune’s application in the top 6.6% of submissions.

“Receiving this award from such a highly competitive pool clearly demonstrates the innovation and groundbreaking work we are doing at VerImmune to develop therapies for patients with unmet medical needs," said Joshua Wang, Founder and CEO of VerImmune, Inc. "We are committed to advancing our ViP platform to address critical healthcare challenges and look forward to utilizing this funding to drive our efforts in melanoma and other cancers.”